Drugs / Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02452307 | Apr 2004 → Oct 2017 | prostate carcinoma | University Hospital Tuebingen | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01368276 Comparator | Oct 2010 → Sep 2014 | melanoma | BioVex Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Granulocyte macrophage colony stimulating factor (GM-CSF) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02452307 ↗ |
| Route | Subcutaneous | “125 µg/m² subcutaneous injection” NCT01368276 ↗ |